AP679A - Oral 2-methyl-thieno-benzodiazepine formulation. - Google Patents

Oral 2-methyl-thieno-benzodiazepine formulation. Download PDF

Info

Publication number
AP679A
AP679A APAP/P/1997/001064A AP9701064A AP679A AP 679 A AP679 A AP 679A AP 9701064 A AP9701064 A AP 9701064A AP 679 A AP679 A AP 679A
Authority
AP
ARIPO
Prior art keywords
formulation
olanzapine
cellulose
hydroxypropyl
methylcellulose
Prior art date
Application number
APAP/P/1997/001064A
Other versions
AP9701064A0 (en
Inventor
George Randall Cochran
Tommy Clifford Morris
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23624847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP679(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AP9701064A0 publication Critical patent/AP9701064A0/en
Application granted granted Critical
Publication of AP679A publication Critical patent/AP679A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

A pharmaceutically elegant stable polymorph formulation of olanzapine of formula i and process for making such formulation.

Description

-1ORAL 2-METHYL-THIENO-BENZODIAZEPINE FORMULATION
This invention provides an improved 5 pharmaceutically elegant tablet formulation of 2-methyl-4-(4methyl-l-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine, hereinafter referred to as olanzapine, and processes for the preparation thereof.
Olanzapine has shown great promise in the treatment of psychotic patients and is currently being evaluated for that purpose. Certain tablet formulations of olanzapine are known, as described in U.S. Patent No. 5,229,382. However, improved oral formulations were desired in light of the moisture sensitive, metastable nature of olanzapine, the tendency of olanzapine to undesirably discolor in the known tablet formulation, and due to the surprisingly potent nature of olanzapine.
The presently claimed invention provides a pharmaceutically elegant solid oral formulation for comprising olanzapine intimately mixed with a bulking agent, binder, disintegrant, a dry binder to provide friability, and : a lubricant; wherein such solid oral formulation is coated
.. 3 with polymer selected from the group consisting of hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methylhydroxyethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, polyvinyl pyrrolidone, difljethylaminoethyl methacrylatemethylacrylate acid ester copolymer, ethylacrylate-methylmethacrylate copolymer, methylcellulose, and ethylcellulose.
It is particularly preferred that the polymer coat does not contain polyethylene glycol.
Further, the invention provides a method for preparing pharmaceutically elegant, stable solid oral olanzapine formulations having a polymer coat selected from the group consisting of hydroxypropyl methyl cellulose,
AP/P/ 97/01064
AP . 0 0 6 7 9
-2hydroxyethyl cellulose, methylhydroxyethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, polyvinyl pyrrolidone, dimethylaminoethyl methacrylatemethylacrylate acid ester copolymer, ethylacrylate-methylmethacrylate copolymer, methyicellulose, and ethylcel-lulose, comprised of using a high shear aqueous wet granulation with fluid bed drying process.
Olanzapine, a potent compound showing promising 10 activity for use in treating psychotic patients, tends to be metastable, undergo pharmaceutically undesired discoloration, and demands care to assure homogeniety of the finished solid formulation.
Applicants have discovered that olanzapine 15 undergoes undesirable discoloration when contacted with certain excipients including powder blends. Further, the discoloration is exacerbated by ambient air conditions, at elevated temperatures, and by moist environments.
Although the discoloration phenomenon does not 20 produce an increase in the number of total related substances, the browning and mottling appearance is not generally considered pharmaceutically acceptable for commercial purposes. Further, the discoloration is X.
particularly disturbing when a tablet formulation is '-'725 administered to a psychotic patient, which patient may be especially troubled by the changing appearance of their medication.
Applicants have discovered that coating the solid 'Oral formulation with a polymer selected from the group consisting of hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methylhydroxyethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, polyvinyl pyrrolidone, dimethylaminoethyl methacrylatemethylacrylate acid ester copolymer, ethylacrylate-methylmethacrylate copolymer, methyicellulose, and ethylcellulose as a coating or subcoating provides a uniform, physical stability and effectively prevents the undesired discoloration phenomenon
AP/P/ 9 7 / 0 1 0 6 4
AP.00679
-3in the formulation. The formulation is most preferredly in a tablet form; however, granule formulation and the like are desired as well.
Most preferred polymer coats are hydroxypropyl 5 methyl cellulose, hydroxypropylcellulose„ methylcellulose, and ethylcellulose. An especially preferred polymer coat is hydroxypropyl methylcellulose.
It is especially preferred that the formulation contain the most stable anhydrous form of olanzapine, referred to herein as Form II; however, other forms of olanzapine are contemplated. Form II has a typical x-ray powder diffraction pattern as represented by the following interplanar spacings:
d
10.2689
8.577
7.4721
7.125
6.1459
6.071
5.4849
5.2181
5.1251
4.9874
4.7665 .4.7158
4.4787
4.3307
4.2294
4.141
3.9873
AP/P/ 97/01064
F
AP.00679
-4d
3.7206
3.5645
3.5366
3.3828
3.2516
3.134
3.0848
3.0638
3.0111
2.8739
2.8102
2.7217
2.6432
2.6007
A typical example of an x-ray diffraction pattern for Form II is as follows wherein d represents the interplanar spacing and I/Ii represents the typical relative intensities :
d I/Il
10.2689 100.00
8.577 7.96
7.4721 1.41
7.125 6.50
6.1459 3.12
6.071 5.12
5.4849 0.52
5.2181 6.86
5.1251 2.47
4.9874 7.41
4.7665 4.03
4.7158 6.80
4.4787 14.72
4.3307 1.48
AP/P/ 9 7 / 0 1 0 6 4
AP.00679
4.2294 23.19
4.141 11.28
d I/Il
3.9873 9.01
3.7206 14.0*4
3.5645 2.27
3.5366 4.85
3.3828 3.47
3.2516 1.25
3.134 0.81
3.0848 0.45
3.0638 1.34
3.0111 3.51
2.8739 0.79
2.8102 1.47
2.7217 0.20
2.6432 1.26
2.6007 0.77
The x-ray diffraction patterns set out herein were obtained using a Siemens D5000 x-ray powder diffractometer having a copper Kq radiation source of wavelength, λ=1·54ΐΑ. 5 The formulation of the invention preferredly contains substantially pure Form II as the active ingredient.
As used herein substantially pure refers to Form II associated with less than about 5% undesired polymorphic form of olanzapine (herein referred to as Undesired Form), 10 preferably less than about 2% Undesired Form, and more ’^Jteferably less than about 1% Undesired Form. Further, substantially pure Form II will contain less than about 0.5% related substances, wherein related substances refers to undesired chemical impurities or residual solvent or water. In particular, substantially pure Form II preferably contain less than about 0.05% content of acetonitrile, more preferably, less than about 0.005% content
AP/P/ 97 / 0 1 0 6 6
AP.00679
-6of acetonitrile. Additionally, Form II preferredly contain less than 0.5% of associated water.
As used herein, the term mammal shall refer to the Mammalia class of higher vertebrates. The term mammal includes, but is not limited to, a human.- The term treating as used herein includes prophylaxis of the named condition or amelioration or elimination of the condition once it has been established.
Form II is the most stable anhydrous form of 10 olanzapine known and is therefore important for the commercial development of pharmaceutically elegant formulations. Olanzapine may form an undesired crystal form in the presence of certain solvents and excipients, therefore, in making the compositions of the invention it is most desired to prepare the formulation using a method which does not require dissolution of the olanzapine substance. The desired Form II can be converted to less desirable polymorphic forms by contact with methylene chloride, for example. Additionally, for example, polyethylene glycol contact with the olanzapine substance produces undesired discoloration, particularly under moist conditions .
Applicants believe that a dry blend direct compression process or dry granulated processes for ^5 preparing solid oral formulations create a greater chance that poor dose uniformity will occur. In light of the potent nature of olanzapine, consistent dose uniformity is imperitive. In accordance with this invention, Applicants have discovered that a high shear aqueous wet granulation with fluid bed drying is the most effective method for preparing pharmaceutically elegant, stable, oral olanzapine formulations .
Uncoated tablets stored at ambient conditions (approximately 23°C and 40% relative humidity) in amber, high density polyethylene bottles do not show signs of discoloration after 24 months; however, if the bottle is
AP/P/ 9 7 / 0 1 0 6 4
AP.00679
-7opened such that the tablets are exposed to open air ambient conditions then discoloration occurs within 5 days.
A new solid oral formulation was prepared that used a hydroxypropropyl methylcellulose subcoating and a white color coating. The new formulation did not discolor after 90 days of open dish storage at 40°C, 60°C, 40°C/75 %RH, ambient temperature with 75% RH, or at ambient temperature with 85% RH. The hydroxypropyl methylcellulose coating which is free of polyethylene glycol is much preferred to ensure that discoloration does not occur on the tablet surface. It provides an effective barrier between the white color coat which provides an acceptable medium for imprinting and color dressing of the product.
The hydroxypropylmethylcellulose coating provides sufficient barrier to prevent discoloration attributable to the polyethylene glycol in the white color coat.
Alternative white film coat formulas containing alternative plasticizers were evaluated; however, none were able to prevent discoloration in all test conditions after 90 days of storage. Therefore, the hydroxypropyl methylcellulose coat or subcoating is a surprising and important component of pharmaceutically elegant solid oral formulations of olanzapine.
'5 A diluent or bulking agent should be selected to <)25 provide an increase in tablet size. The artisan can utilize known methods to select a bulking agent which provides hardness, friability, and disintegration time that is satisfactory for pharmaceutical usage. The bulking ^gent should be selected to provide a tablet that has characterstics desired by the patient as well as comply with applicable regulatory guidelines.
One especially preferred diluent or bulking agent is lactose. Various forms of lactose are appropriate for such formulations including anhydrous, hydrous, and spray dried forms. The most desired form of lactose can be selected based on desired dissolution, content uniformity, hardness, friability, and disintegration time. The skilled
AP/P/ 9 7 / 0 1 0 6 4
AP.00679
-8artisan is aware of the regulatory requirements for hardness, friability, and disintegration time and can adjust the diluent or bulking agents using known techniques to achieve the desired physical characteristics.
The formulation should include -a binder for use in the granulation step. The artisan can choose an appropriate binder based on the acceptable viscosity, and desired hydration. Hydroxypropyl cellulose is especially preferred for use as a binder in the granulation step. The hydroxypropyl cellulose may vary in particle size. Fine grade hydroxypropyl cellulose is especially preferred for most claimed formulations.
The desired formulation includes a disintegrant for use in the granulation as well as in the running powders to facilitate the disintegration process. There are a variety of grades available, and the grade may be selected based on the acceptable batch variability. A particularly prefered disintegrant is crospovidone. A fine grade of crospovidone provides particularly desirable consistency between batches.
The artisan may choose appropriate dry binders using known methods. Such binders should be selected to assure that satisfactory friability is attained. Most preferably, dry binder is microcrystalline cellulose;
‘.15 however, other appropriate dry binders may be selected.
Such microcrystalline cellulose may be in a granular form.
The artisan can choose an appropriate lubricant to prevent sticking and picking of the tablets to the oompression tooling. One preferred lubricant is magnesium stearate.
The artisan can readily choose other appropriate aqueous dispersion film coats (color mix) for application over the hydroxypropyl methylcellulose layer. Typically, the color mixture is a dry blend of ingredients which may be dispersed in water and used as an aqueous dispersion to film coat solid formulations. One example of a typical color mixture is comprised of hydroxypropyl
AP/P/ 9 7 / 0 1 0 6 4
AP.00679
-9methylcellulose, polyethylene glycol, polysorbate 80, and titianium dioxide.
A variety of edible inks known to the artisan are appropriate for imprinting the finished formulation.
For example, one typical edible ink is comprised of shellac, ehtyl alcohol, isopropyl alcohol, n-butyl alcohol, propylene glycol, ammonium hydroxide, and FD&C Blue.
The solid formulation is most preferably subcoated with hydroxypropyl methylcellulose, coated with a 10 color coat, and imprinted with an edible ink. The solid formulation may be polished using standard methods such as carnauba wax polishing, if desired.
Olanzapine is effective over a wide dosage range, the actual dose administered being dependent on the 15 condition being treated. For example, in the treatment of adult humans, dosages of from about 0.25 to 50 mg, preferably from 1 to 30 mg, and most preferably 1 to 20 mg per day may be used. A once a day dosage is normally sufficient, although divided doses may be administered.
For treatment of central nervous system disorders, a dose range of from 1 to 30 mg, preferably 1 to 20 mg per day is suitable. Radiolabelled Form II 2-methyl-4-(4-methyl-lpiperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, can be detected in the saliva and thus the compound can ;?25 potentially be monitored in patients to assess compliance.
A preferred formulation of the invention is a solid oral formulation comprising from about 1 to about 2.0 mg olanzapine as an active ingedient, wherein such solid T>ral formulation is coated with hydroxypropyl methylcellulose. Especially preferred is an oral formulation comprising from 1 to 20 mg of anhydrous Form II olanzapine as an effective amount of the active ingredient, provided that such solid oral formulation is coated with hydroxypropyl methylcellulose.
Most preferably, the solid oral formulation is contained in packaging materials which protect the formulation from moisture and light. For example, suitable
AP/P/ 97/01064
AP.00679
-10packaging materials include amber colored high densitypolyethylene bottles, amber colored glass bottles, and other containers made of a material which inhibits the passage of light. Most preferably, the packaging will include a desiccant pack. The container may be sealed with an aluminum foil blister to provide the desired protection and maintain product stability.
A study of the hydroxypropyl methylcellulose subcoated tablets in an amber colored bottle having a desiccant pack stored at harsh, 40°C/75% RH conditions for six months showed pharmaceutically acceptable stability with a 0.4 % to about 1.2% increase in total related substances.
The materials for the present invention can be purchased or prepared by a variety of procedures well known to those of ordinary skill in the art. Olanzapine can be prepared as described by Chakrabarti in U.S. Patent No 5,229,382 ('382), herein incorporated by reference in its entirety. It is most desirable to prepare a rapidly dissolving formulation comprising substantially pure crystalline Form II. Such substantially pure crystalline
Form II olanzapine may be prepared using the techniques described herein by the Preparation section herein infra.
Compound characterization methods include, for example, x-ray powder pattern analysis, thermogravimetric ;2 5 analysis (TGA), differential scanning calorimetery (DSC), titrametric analysis for water, and H1-NMR analysis for solvent content.
The formulations were studied to assure that the Form II polymorph was substantially pure using 13C Cross polarization / magic angle spinning (CP/MAS) NMR. Spectra were obtained using a Varian Unity 400 MHz spectrometer operating at a carbon frequency of 100.577 MHz and equipped with a complete solids accessory and Varian 5 mm or 7 mm VT CP/MAS probes. Measurement conditions were optimized for
Olanzapine Form II and were as follows: 90° proton r.f.
pulse 4.5 ms, contact time 1.1 ms, pulse repetition time 5 s, MAS frequency 7.0 kHz, spectral width 50 kHz, and acquisition
AP/P/ 9 7 / 0 1 0 6 4
AP.00679
-11time 50 ms. Chemical shifts were referenced to the CH3 of hexamethylbenzene (d = 17.3 ppm) by sample replacement. It was determined that the substantially pure Form II polymorph is retained throughout the formulation process claimed herein. Therefore, the formulations of this invention provide substantially pure Form II olanzapine polymorph in a pharmaceutically elegant formulation without producing undesired polymorphic transformation.
The following examples are provided for purposes of 10 illustration and are not to be construed as limiting the scope of the claimed invention.
Preparation 1
Technical Grade olanzapine
AP/P/ 9 7 / 0 1 0 6 4
In a suitable three neck flask the following was added:
Dimethylsulfoxide (analytical): 6 volumes
Intermediate 1 : 75 g
N-Methylpiperazine (reagent) : 6 equivalents
Intermediate 1 can be prepared using methods known to the skilled artisan. For example, the preparation of the
Intermediate 1 is taught in the '382 patent.
AP.00679
-12A sub-surface nitrogen sparge line was added to remove the ammonia formed during the reaction. The reaction was heated to 120°C and maintained at that temperature throughout the duration of the reaction. The reactions were followed by
HPLC' until < 5% of the intermediate 1 was- left unreacted.
After the reaction was complete, the mixture was allowed to cool slowly to 20°C (about 2 hours). The reaction mixture was then transferred to an appropriate three neck round bottom flask and water bath. To this solution with agitation was added 10 volumes reagent grade methanol and the reaction was stirred at 20°C for 3 0 minutes. Three volumes of water was added slowly over about 30 minutes. The reaction slurry was cooled to zero to 5°C and stirred for 30 minutes. The product was filtered and the wet cake was washed with chilled methanol. The wet cake was dried in vacuo at 45°C overnight.
The product was identified as technical olanzapine.
Yield: 76.7%; Potency: 98.1%
Preparation 2
Form II
A 270 g sample of technical grade 2-methyl-4-(4methyl-1-piperazinyl)-10H-thieno[2, 3-b][1,5]benzodiazepine was suspended in anhydrous ethyl acetate (2.7 L) . The mixture was heated to 76°C and maintained at 76°C for 30 minutes. The mixture was allowed to cool to 25°C. The resulting product was isolated using vacuum filtration. The product was identified as Form II using x-ray powder analysis.
Yield: 197 g.
The process described above for preparing Form II provides a pharmaceutically elegant product having potency > 97%, total related substances < 0.5% and an isolated yield of > 73%.
AP/P/ 9 7 / 0 1 0 6 4
AP.ΟΟ679
-13EXAMPLE 1
A portion of the hydroxypropyl cellulose was dissolved in purified water to form a solution for granulation. The remaining hydroxypropyl-cellulose (total of
4.0% w/w final tablet weight), which was an extra fine grade, was combined with the olanzapine (1.18% w/w), lactose (79.32% w/w) and a portion of the crospovidone (5% w/w) in a high shear granulator. All ingredients were security sieved prior to addition and dry blended in the granulator. This mixture was then granulated with the hydroxypropyl cellulose solution in the high shear granulator. The granulation was wet sized using standard methods. The wet granulation was then dried in a fluidized bed dryer and sized. The material was then added to a tumble bin mixer.
The running powders consisting of microcrystalline cellulose (granular) (10% w/w), magnesium stearate (0.5% w/w), and the remainder of the crospovidone were added to the sized granulation. The mixture was blended and compressed with the appropriate tooling on tablet compression equipment.
Subcoating:
'25 Hydroxypropyl methylcellulose (10% w/w) was mixed with purified water to form a solution. Core tablets were divided into approximately equal sections and spray coated with the hydroxypropyl methylcellulose solution . The operation was performed in a perforated coating pan.
Coating of Core Tablets:
Color Mixture White (hydroxypropy1 methylcellulose, polyethylene glycol, polysorbate 80, and titanium dioxide) was mixed with purified water to form the coating suspension. Subcoated tablets were divided into approximately equal sections and spray coated with the coating suspension
AP/P/ 9 7 / 0 1 0 6 4
AP.OO679
-14described above. The operation was performed in a perforated coating pan.
The coated tablets were lightly dusted with carnauba wax and 5 imprinted with appropriate identification.'
EXAMPLE 2
The process substantially as described above in
Example 1 was repeated using the following ingredients to provide pharmaceutically elegant tablet formulations containing 1, 2.5, 5, 7.5, and 10 mg olanzapine, respectively, per tablet:
1 mo olanzapine per tablet:
Names of Ingredients Quantity (rag/tab let)
Active Ingredient Olanzapine 1.0
Other Ingredients Lactose 67.43
Hydroxy propyl 3.40
Cellulose Crospovidone 4.25
Microcrystalline 8.50
Cellulose Magnesium Stearate 0.42
Subcoating Hy droxypfopyl 1.70
Methylcellulose Coating Color Mixture White 3.47
Polishing Carnauba Wax trace
Imprinting Edible Blue Ink trace
AP/P/ 9 7 / 0 1 0 6 4
AP.00679
-15Olanzapine 2.5 mg Tablets
Names of Ingredients Quantity ( m g /1 a b let)
Active Ingredient Olanzapine 2.5
Other Ingredients Lactose 102.15
Hydroxypropyl 5.20
Cellulose Crospovidone 6.50
Microcrystalline 13.00
Cellulose Magnesium Stearate 0.65
Subcoating Hydroxypropyl 2.60
Methylcellulose Coating Color Mixture White 5.30
Polishing Camauba Wax trace
Imprinting Edible Blue Ink trace
Olanzapine 5.0 mg Tablets
Names of Ingredients Quantity (m g/tab let)
Active Ingredient Olanzapine 5.00
Other Ingredients Lactose 156.00
Hydroxypropyl 8.00
Cellulose Crospovidone 10.00
‘Microcrystalline 20.00
Cellulose Magnesium Stearate 1.00
Su bcoating Hydroxypropy 1 4.00
Methylcellulose Coating Color Mixture White 8.16
Polishing Camauba Wax trace
Imprinting Edible Blue Ink trace
AP/P/ 9 7 / 0 1 0 6 4
AP .00679
Olanzapine 7,5 ma Tablets
Names of Ingredients Quantity ( m g /1 a b let)
Active Ingredient Olanzapine 7.50
Other Ingredients Lactose 234.00
Hydroxypropyl Cellulose 12.00
Crospovidone 15.00
Microcrystalline Cellulose 30.00
Magnesium Stearate Subcoating 1.50
Hydroxypropyl Methylcellulose Coating 6.00
Color Mixture White 12.24
Polishing Camauba Wax trace
Imprinting Edible Blue Ink trace
Olanzapine 10.0 mg Tablets
Names of Ingredients Quantity ( m g /1 a b let)
Active Ingredient Olanzapine 10.00
Other Ingredients Lactose 312.00
Hydroxypropy 1 Cellulose 16.00
Crospovidone 20.00
Microcrystalline Cellulose 40.00
Magnesium Stearate Subcoating 2.00
Hydroxypropyl Methylcellulose 8.00
Coating Color Mixture White 16.32
Polishing Camauba Wax trace
Imprinting Edible Blue Ink trace
AP/P/ 9 7 / 0 1 0 6 4

Claims (17)

1. A solid oral formulation comprising olanzapine as an active ingredient intimately mixed with a bulking agent; binder, disintegrant, a dry binder to assure adequate friability, and a lubricant; wherein such solid oral formulation is coated with a polymer selected from the group cosisting of hydroxypropyl methylcellulose, hydroxyethyl cellulose, methylhydroxyethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, polyvinyl pyrrolidone, dimethylaminoethyl methacrylatemethylacrylate acid ester copolymer, ethylacrylate-methylmethacrylate copolymer, methylcellulose, and ethylcellulose.
2.6007
2.6432
2.7217
2.8102
2.8739
2. A formulation as claimed by Claim 1 wherein the polymer coat is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropylcellulose, methylcellulose, and ethylcellulose
3.0111
3.0638
3.0848
3.134
3.2516
3.3828
3.5366
3.5645
3.7206
3.9873
3. A formulation as claimed by Claim 2 wherein the polymer coat is hydroxypropylmethyl cellulose.
AP/P/ 9 7 / 0 1 0 6 4
4.141
4.2294
4.3307
4.3307 4.2294 4.141 3.9873 3.7206 3.5645 3.5366
AP/P/ 9 7 / 0 1 0 6 4
AP.00679
-193.3828 3.2516 3.134 3.0848 3.0638 3.0111 . 2.8739 2.8102 2.7217 2.6432 2.6007
4.7158 x* 4.4787
4.7665
4.9874
4 . A formulation as claimed by any one of Claims 1 to 3 wherein the polymer coat is free of propylene glycol. 5 . A formulation as claimed by Claim 4 wherein the bulking agent is lactose. 6 . A formulation as claimed by Claim 4 wherein the
binder is hydroxypropyl cellulose and the disintegrant is crospovidone.
5.1251
5.2181
5.4849
6.071 5.4849 5.2181 5.1251 4.9874 4.7665 4.7158
AP/P/ 9 7 / 0 1 0 6 4
AP.00679
-204.4787
6.071
6.1459
6 wherein the dry binder is microcrystalline cellulose.
7.125 x* 6.1459
7.4721
7.125
7.4721
7 wherein the lubricant is magnesium stearate.
7. A formulation as claimed by any one.of Claims 1 to
8.577
8.577
8 wherein the hydroxypropyl methylcellulose is a subcoating which is further coated with a aqueous dispersion film coat.
AP.00679
-Ιδιο. A formulation as claimed by Claim 9 wherein the solid formulation is imprinted using an edible ink.
8. A formulation as claimed by any one of Claims 1 to
9. A formulation as claimed by any one of Claims 1 to
10.2689
10.2689
11. A formulation as claimed by Claim 9 wherein the formulation comprises from about 1 to about 3 % w/w olanzapine; from about 69.5 to about 87.5 % w/w lactose; from about 3.5 to about 4.5 % w/w hydroxypropyl cellulose; from about 4 to about 6 % w/w crospovidone; from about 9 to about 11 % w/w microcrystalline cellulose; and from about 0.25 to about 1 % magnesium stearate.
12. A formulation as claimed by any one of Claims 1 to 11 wherein the solid formulation is a tablet.
13. A formulation as claimed by Claim 12 wherein each tablet provides a dose of olanzapine selected from the group consisting of 1, 2.5, 5, 7.5, 10, 15, and 20 mg.
14. A formulation as claimed by any one of Claims 1 to 13 wherein olanzapine is substantially pure Form II polymorph having a typical x-ray powder diffraction pattern as represented by the following interplanar spacings:
d (A)
15. A process for preparing a stable pharmaceutically elegant solid oral formulation containing olanzapineas an active ingredient and having a polymer coating selected from the group consisting of hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methylhydroxyethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, polyvinyl pyrrolidone, dimethylaminoethyl methacrylatemethylacrylate acid ester copolymer, ethylacrylate-methylmethacrylate copolymer, methyicellulose, and ethylcellulose, comprising high shear aqueous wet granulation with fluid bed drying.
16. A process as claimed by Claim 15 wherein olanzapine is substantially pure Form II polymorph having a typical x-ray powder diffraction pattern as represented by the following interplanar spacings:
d (A)
17. A solid formulation as claimed by any one of Claims 1 to 14 for use in treating a condition selected from the group consisting of psychosis, schizophrenia, a schizophriform disorder, mild anxiety, a gastrointestinal disorder, and acute mania.
APAP/P/1997/001064A 1995-03-24 1996-03-22 Oral 2-methyl-thieno-benzodiazepine formulation. AP679A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41046595A 1995-03-24 1995-03-24
PCT/US1996/003918 WO1996029995A1 (en) 1995-03-24 1996-03-22 Oral 2-methyl-thieno-benzodiazepine formulation

Publications (2)

Publication Number Publication Date
AP9701064A0 AP9701064A0 (en) 1997-10-31
AP679A true AP679A (en) 1998-09-28

Family

ID=23624847

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001064A AP679A (en) 1995-03-24 1996-03-22 Oral 2-methyl-thieno-benzodiazepine formulation.

Country Status (46)

Country Link
US (4) US5919485A (en)
EP (2) EP0733367B1 (en)
JP (1) JPH11502848A (en)
KR (1) KR100408172B1 (en)
CN (1) CN1178662C (en)
AP (1) AP679A (en)
AR (2) AR001405A1 (en)
AT (3) ATE206924T1 (en)
AU (1) AU696601B2 (en)
BG (1) BG62594B1 (en)
BR (1) BR9607791A (en)
CA (1) CA2216372C (en)
CH (1) CH691217A5 (en)
CO (1) CO4700474A1 (en)
CR (1) CR5278A (en)
CZ (1) CZ296007B6 (en)
DE (3) DE19681287T1 (en)
DK (3) DK0733367T3 (en)
EA (1) EA000938B1 (en)
EE (1) EE03551B1 (en)
EG (1) EG24077A (en)
ES (2) ES2232379T3 (en)
FI (1) FI973749A (en)
GB (1) GB2313783B (en)
HU (1) HU225269B1 (en)
IL (1) IL117611A (en)
IS (1) IS1903B (en)
LT (1) LT4350B (en)
LU (1) LU90115B1 (en)
LV (1) LV11983B (en)
MY (1) MY113440A (en)
NO (1) NO320388B1 (en)
NZ (1) NZ306111A (en)
OA (1) OA10511A (en)
PE (1) PE44997A1 (en)
PL (1) PL188316B1 (en)
PT (2) PT733367E (en)
RO (1) RO118370B1 (en)
SE (1) SE9703206L (en)
SI (3) SI1093815T1 (en)
SK (1) SK283745B6 (en)
TR (1) TR199701018T1 (en)
TW (1) TW426526B (en)
UA (1) UA44766C2 (en)
WO (1) WO1996029995A1 (en)
ZA (1) ZA962338B (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR5278A (en) * 1995-03-24 1996-07-04 Lilly Co Eli ORAL FORMULATION OF 2-METHYL-THENO-BENZODIACEPINE
CN1230883A (en) * 1996-09-24 1999-10-06 伊莱利利公司 Coated particle formulation
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
AU779452B2 (en) * 1999-12-28 2005-01-27 Cipla Limited New polymorphic forms of olanzapine
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
US20030072729A1 (en) * 2001-05-15 2003-04-17 Christopher Szymczak Simethicone as weight gain enhancer
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
CN1649614A (en) 2002-02-22 2005-08-03 新河药品股份有限公司 Active agent delivery systems and methods for protecting and administering active agents
WO2003086361A1 (en) * 2002-04-18 2003-10-23 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
ATE500258T1 (en) 2002-05-31 2011-03-15 Sandoz Ag METHOD FOR PRODUCING OLNZAPINE FORM I
SI21270A (en) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Crystal forms of olanzapine and procedures for their preparation
US7029112B2 (en) * 2002-08-05 2006-04-18 Mars, Incorporated Ink-jet printing on surface modified edibles and products made
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
PL202856B1 (en) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Method of obtaining pharmaceutically pure polymorphic form of I olanzapine
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
EP1670441A4 (en) * 2003-10-07 2012-05-02 Andrx Pharmaceuticals Llc Rapidly disintegrating formulation
CA2546200A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
ES2253091B1 (en) * 2004-07-27 2007-02-01 Inke, S.A. MIXED SOLVATO OF OLANZAPINE, PROCEDURE FOR OBTAINING AND PROCEDURE OF OBTAINING THE FORM I OF OLANZAPINE FROM THE SAME.
US7932249B2 (en) 2005-01-05 2011-04-26 Eli Lilly And Company Olanzapine pamoate dihydrate
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US20060240101A1 (en) * 2005-04-22 2006-10-26 Shubha Chungi Orally disintegrating pharmaceutical tablet formulations of olanzapine
JP4938005B2 (en) * 2005-05-31 2012-05-23 ザ・アイムス・カンパニー Lactobacillus, a feline probiotic
JP4938006B2 (en) * 2005-05-31 2012-05-23 ザ・アイムス・カンパニー Feline probiotic bifidobacteria
US20070014847A1 (en) * 2005-07-05 2007-01-18 Ahmed Salah U Coated capsules and methods of making and using the same
JP2009502807A (en) * 2005-07-22 2009-01-29 ミリアド ジェネティクス， インコーポレイテッド Formulations and dosage forms with high drug content
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (en) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. ORAL FORMULATION OF OLANZAPINE.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
WO2008004033A1 (en) * 2006-07-05 2008-01-10 Bilim Ilac Sanayii Ve Ticaret A.S. A stable olanzapine formulation with antioxidants
AR063043A1 (en) * 2006-09-29 2008-12-23 Synthon Bv PHARMACEUTICAL COMPOSITION OF OLANZAPINA
WO2008093303A2 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
DK2246051T3 (en) * 2008-01-31 2014-01-13 Kyorin Seiyaku Kk Process for the preparation of oral fast-dissolving tablet comprising imidafenacin as active ingredient
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8505322B2 (en) * 2009-03-25 2013-08-13 Pax Scientific, Inc. Battery cooling
US20110048048A1 (en) * 2009-03-25 2011-03-03 Thomas Gielda Personal Cooling System
GB2473981B (en) * 2009-03-25 2012-02-22 Caitin Inc Thermodynamic cycle for cooling a working fluid
US20110051549A1 (en) * 2009-07-25 2011-03-03 Kristian Debus Nucleation Ring for a Central Insert
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8365540B2 (en) * 2009-09-04 2013-02-05 Pax Scientific, Inc. System and method for heat transfer
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9517212B1 (en) * 2012-11-15 2016-12-13 Chandra Zaveri Medicated adhesive pad arrangement
CN103919782B (en) * 2013-01-15 2016-12-28 天津药物研究院有限公司 A kind of pharmaceutical composition containing olanzapine and preparation method thereof
EP3043778B1 (en) * 2013-09-13 2017-09-06 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
CN107007559B (en) * 2017-04-21 2020-05-15 浙江京新药业股份有限公司 Stable oral pharmaceutical composition and preparation method thereof
CN110709061B (en) * 2017-06-02 2023-09-08 Xeris药物公司 Anti-precipitation small molecule pharmaceutical formulations
CN113143878A (en) * 2021-03-19 2021-07-23 杭州新诺华医药有限公司 Olanzapine composition and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172831A (en) * 1974-11-26 1979-10-30 Lilly Industries Limited Thieno-benzodiazepines
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
ZA922777B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical formulation containing dirithromycin
JPH05194225A (en) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd Stabilized antiulcer agent-containing preparation
DE69329887T2 (en) * 1992-05-29 2001-05-23 Eli Lilly And Co., Ltd. Thienobenzodiazepine derivatives for the treatment of disorders of the central nervous system
SE9302395D0 (en) * 1993-07-09 1993-07-09 Ab Astra NEW PHARMACEUTICAL FORMULATION
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
CR5278A (en) * 1995-03-24 1996-07-04 Lilly Co Eli ORAL FORMULATION OF 2-METHYL-THENO-BENZODIACEPINE
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172831A (en) * 1974-11-26 1979-10-30 Lilly Industries Limited Thieno-benzodiazepines
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
HU225269B1 (en) 2006-08-28
TW426526B (en) 2001-03-21
DK173323B1 (en) 2000-07-24
CO4700474A1 (en) 1998-12-29
CZ296007B6 (en) 2005-12-14
SI0733367T1 (en) 2002-06-30
AT405606B (en) 1999-10-25
IS4565A (en) 1997-09-22
US6190698B1 (en) 2001-02-20
DE69615887T2 (en) 2002-04-11
PE44997A1 (en) 1997-10-23
CA2216372C (en) 2007-11-20
FI973749A0 (en) 1997-09-22
KR19980703189A (en) 1998-10-15
ATE206924T1 (en) 2001-11-15
BG101901A (en) 1998-10-30
ES2164837T3 (en) 2002-03-01
AU5428096A (en) 1996-10-16
ATA902296A (en) 1999-02-15
CN1178662C (en) 2004-12-08
DE69634053T2 (en) 2005-12-22
TR199701018T1 (en) 1998-01-21
US6780433B2 (en) 2004-08-24
CN1179102A (en) 1998-04-15
LT4350B (en) 1998-05-25
EP0733367B1 (en) 2001-10-17
SE9703206D0 (en) 1997-09-05
US20010018071A1 (en) 2001-08-30
NO974363D0 (en) 1997-09-22
EA000938B1 (en) 2000-06-26
EP1093815B1 (en) 2004-12-15
CZ300197A3 (en) 1997-12-17
PT733367E (en) 2002-03-28
DK0733367T3 (en) 2001-11-26
NZ306111A (en) 1999-02-25
CA2216372A1 (en) 1996-10-03
BR9607791A (en) 1998-07-07
ES2232379T3 (en) 2005-06-01
FI973749A (en) 1997-09-22
EE03551B1 (en) 2001-12-17
NO320388B1 (en) 2005-11-28
JPH11502848A (en) 1999-03-09
EP1093815A1 (en) 2001-04-25
AU696601B2 (en) 1998-09-17
LT97149A (en) 1998-01-26
IL117611A (en) 2002-05-23
IS1903B (en) 2003-11-20
SI9620041A (en) 1998-06-30
PT1093815E (en) 2005-03-31
MY113440A (en) 2002-02-28
NO974363L (en) 1997-11-17
PL188316B1 (en) 2005-01-31
UA44766C2 (en) 2002-03-15
MX9707186A (en) 1997-11-29
US20050085462A1 (en) 2005-04-21
EG24077A (en) 2008-05-11
LV11983A (en) 1998-03-20
LU90115B1 (en) 1997-09-10
GB2313783B (en) 1998-11-18
DE19681287T1 (en) 1998-03-19
AP9701064A0 (en) 1997-10-31
US5919485A (en) 1999-07-06
SE9703206L (en) 1997-09-05
ZA962338B (en) 1997-09-22
ATE284695T1 (en) 2005-01-15
EP0733367A1 (en) 1996-09-25
DE69634053D1 (en) 2005-01-20
PL322579A1 (en) 1998-02-02
SK128297A3 (en) 1998-03-04
CH691217A5 (en) 2001-05-31
EE9700328A (en) 1998-06-15
BG62594B1 (en) 2000-03-31
OA10511A (en) 2002-04-24
WO1996029995A1 (en) 1996-10-03
DK109097A (en) 1997-11-12
DE69615887D1 (en) 2001-11-22
LV11983B (en) 1998-07-20
GB2313783A (en) 1997-12-10
SI1093815T1 (en) 2005-06-30
EA199700260A1 (en) 1998-02-26
HUP9800410A2 (en) 1998-07-28
CR5278A (en) 1996-07-04
IL117611A0 (en) 1996-07-23
RO118370B1 (en) 2003-05-30
GB9719817D0 (en) 1997-11-19
HUP9800410A3 (en) 2000-01-28
DK1093815T3 (en) 2005-04-25
KR100408172B1 (en) 2004-02-18
SK283745B6 (en) 2003-12-02
AR001405A1 (en) 1997-10-22
US7229643B2 (en) 2007-06-12
AR002720A1 (en) 1998-04-29

Similar Documents

Publication Publication Date Title
AP679A (en) Oral 2-methyl-thieno-benzodiazepine formulation.
AU719788B2 (en) Coated particle formulation
EP0900085B1 (en) Treatment of excessive aggression with olanzapine
MXPA97007186A (en) Oral formulation of 2-methyl-tieno-benzodiazep